Crystal Adam, an officer at Tango Therapeutics, Inc., has filed to sell 20,000 shares of the company. This transaction is notable as it reflects Adam's decision to exercise stock options, a common practice among executives. The sale is set against the backdrop of ongoing activities within the pharmaceutical industry.

Background

Tango Therapeutics, Inc. operates in the pharmaceutical preparations sector, specifically categorized under SIC 2834. The company is based in Boston, Massachusetts, and has undergone a name change from BCTG Acquisition Corp. in July 2020. The recent filing, dated November 2, 2026, is part of a series of disclosures made by Adam Crystal, who has been actively managing his holdings in the company.

What the Filing Says

The filing indicates that Adam Crystal plans to sell 20,000 shares of Tango Therapeutics, with an aggregate market value of $454,400. The shares are being sold following the exercise of stock options on the same date. The filing states, "The securities to be sold were and will be received upon the exercise of stock options over the next three months."

Impact

This filing may impact various stakeholders, including investors and analysts watching Tango Therapeutics. Adam Crystal's actions could influence perceptions of the company's leadership and its financial health. Additionally, this move may prompt other executives in the pharmaceutical preparations sector to evaluate their own stock holdings and potential sales.

What's Next

The filing does not say what happens next.